zoledronic acid has been researched along with Primary Myelofibrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Fujii, S; Fujita, M; Hamaguchi, K; Horiguchi, H; Kato, J; Koguma, M; Koguma, T; Kuroda, H; Maeda, M; Nakamura, H; Sato, K; Sugama, Y; Yamada, M; Yamauchi, N | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| Berlanga, J; Domingo, A; Español, I; Heras, L; Janáriz, J; Losa, F; Romagosa, V | 1 |
3 other study(ies) available for zoledronic acid and Primary Myelofibrosis
| Article | Year |
|---|---|
[Zoledronic Acid Administration is Effective for Hematopoiesis Management in a Patient with Primary Myelofibrosis].
Topics: Aged, 80 and over; Biopsy; Diphosphonates; Hematopoiesis; Humans; Imidazoles; Male; Primary Myelofibrosis; Treatment Outcome; Zoledronic Acid | 2016 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Zoledronate-induced remission of acute panmyelosis with myelofibrosis.
Topics: Acute Disease; Aged; Blood Cell Count; Blood Transfusion; Bone Marrow Examination; Diphosphonates; Humans; Imidazoles; Leukemia, Myeloid; Male; Primary Myelofibrosis; Remission Induction; Zoledronic Acid | 2004 |